Yesterday’s webcast conference information is recorded and available for replay on Aveo’s website for two weeks.

FOTIVDA was approved in August 2017 in the European Union and in other countries in the territory of its partner EUSA Pharma (UK) Limited for the treatment of adult patients with advanced RCC. It has demonstrated a significant reduction in regulatory T-cell production in preclinical models.

The drug was discovered by Kyowa Kirin.

For more detailed important safety information, warnings and precautions please visit the firm’s website.

From the Vanderbilt Ingram Cancer Center

Brian Rini, MD, Chief of Clinical Trials at Vanderbilt Ingram Cancer Center and principal investigator of the TIVO-3 trial stated, “FOTIVDA’s approval provides a new tool for treating patients with kidney cancer who have relapsed or become refractory to two or more prior systemic therapies.”  Dr. Rini continued, “With advances in RCC treatment, patients are living longer, increasing the need for proven, well-tolerated treatment options in the relapsed or refractory setting. The TIVO-3 study is the first positive Phase 3 study in RCC patients who received two or more prior systemic therapies, and also the first Phase 3 RCC study to include a predefined population of patients who have received prior immunotherapy, the current standard of care in earlier-line treatment. With this approval, I believe FOTIVDA represents an attractive intervention, and expect it to play a meaningful role in the evolving RCC treatment landscape.”

Prohost Observations 

After soaring yesterday on the approval news, the stock is trading at $12.86, losing more than 15% to profit-taking.

We will have to keep our eyes on this stock for a while before we can fairly evaluate its worth.

Visit our website for other news.